Foghorn Therapeutics Inc. is a clinical-stage biopharmaceutical company dedicated to discovering and developing medicines. Their focus is on addressing genetically determined vulnerabilities within the chromatin regulatory system. The company employs its exclusive "Gene Traffic Control" platform to pinpoint, validate, and strategize drug development for specific targets within this complex system. Its pipeline includes FHD-286, a small-molecule agent engineered to halt the enzymatic activity of BRG1 and BRM. This compound is being developed to treat metastatic uveal melanoma, as well as acute myeloid leukemia and myelodysplastic syndrome that have either recurred or are resistant to previous therapies. Another key candidate, FHD-609, is a small-molecule protein degrader designed to target BRD9, intended for patients diagnosed with synovial sarcoma. Beyond these, Foghorn is also further developing a selective enzymatic inhibitor and a protein degrader, both designed to modulate BRM. Additionally, they are working on ARID1B selective modulators, with potential applications in treating ovarian, endometrial, colorectal, bladder, and gastric cancers. The company has forged strategic alliances, including a research collaboration and licensing agreement with Merck Sharp & Dohme Corp. aimed at unearthing and creating novel oncology therapies focused on a transcription factor target. They also collaborate with Loxo Oncology to devise new cancer treatments. Foghorn Therapeutics Inc. was established in 2015 and maintains its headquarters in Cambridge, Massachusetts.
Foghorn Therapeutics Provides Update on FHD-909 and Strategic Priorities
Foghorn Therapeutics and Eli Lilly will not advance FHD-909 (LY4050784) beyond the Phase 1 dose escalation trial after clinical data failed to show the required efficacy, and the collaboration — including the Selective SMARCA2 degrader program — will not move forward.
Foghorn is now prioritizing its wholly owned pipeline: a Selective EP300 degrader, a novel oral immunology and inflammation program, a Selective CBP degrader, and its induced proximity platform.
The company announced an approximately 40% workforce reduction and organizational changes expected to extend its cash runway into the second half of 2029.
The pipeline cut removes Foghorn's lead partnered program and a key source of collaboration economics, leaving preclinical-stage wholly owned assets as the core value drivers.